Barclays analyst Balaji Prasad reiterated an Overweight rating and $20.00 price target on Teva Pharma (NYSE: TEVA).The analyst commented, "Positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE